Can’t wait for MDT-Bridge results to be public! Jonathan Spicer MD PhD Martin Reck Oncology at AstraZeneca CTSurgSocMedNetwork #lcsm General Thoracic Surgical Club The Society of Thoracic Surgeons AATS UVA Surgery UVA Comprehensive Cancer Center

📢 #ESMO25 concomitant paper: results from the phase III trial of 177Lu-Dotatate vs high-dose octreotide for advanced Grade 1-2 GEP-NETs bit.ly/48osptB

💗 El Instituto Nacional de Cancerología se ilumina de rosa para conmemorar el Día Internacional de la Lucha contra el Cáncer de Mama. Acciones como esta buscan visibilizar la importancia de la detección temprana y la unión de todos en esta causa.

Very proud and happy to share that our work on neoadjuvant IO in pMMR colon cancers has been published online in nature after presentation ESMO - Eur. Oncology #ESMO25. Preview: rdcu.be/eLTN1 Read on how genomic instability, P53mt and proliferation may aid in predicting responses.

Co-chairing #ESMO25 one day, publishing in nature …same day! That is Myriam Chalabi for you ! ESMO - Eur. Oncology The Netherlands Cancer Institute

⚡️ #ESMO25 - ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer #BladderCancer #Immunotherapy ESMO - Eur. Oncology nejm.org/doi/full/10.10…

🤯 New in nature from MD Anderson Cancer Center colleagues Adam Grippin Steven H. Lin SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade nature.com/articles/s4158…

¡Política sanitaria que salva vidas! Revista The Lancet Infectious Diseases destaca a nuestro país por la aplicación del anticuerpo monoclonal contra el Virus Respiratorio Sincicial. Esta política pública ha significado que en Chile por dos años consecutivos (2024-2025) -en el marco de la

Thanks to the CU Cancer Center for highlighting our Global Geriatric Assessment ASCO guidelines! You can read and download them for free here ascopubs.org/doi/10.1200/GO… news.cuanschutz.edu/cancer-center/…

A must-read review on non-clear cell RCC! JCO Oncology Practice 👉doi.org/10.1200/OP-25-… ASCO #Cancer #Oncology OncoAlert Pedro C Barata, MD MSc FACP

ASCENT-03: Sacituzumab Govitecan in Untreated, Advanced Triple-Negative #BreastCancer nejm.org/doi/full/10.10… Presented at #ESMO25 : Finds In patients with advanced triple-negative breast cancer ineligible for PD-1 or PD-L1 inhibitors, sacituzumab govitecan significantly

EMBARK: Overall survival with enzalutamide in biochemically recurrent #ProstateCancer Presented at #ESMO25 cslide.ctimeetingtech.com/esmo2025/atten… Enzalutamide plus leuprolide significantly improves overall survival and delays disease progression compared with leuprolide alone in high-risk

Is this the "turbo cancer" you speak of?

Original Article: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC trial) nej.md/45AU4Wp #Cardiology

The origin of the word “cancer”: the crab🦀 The earliest known record of cancer dates back to 2500–1600 BCE, found in the Edwin Smith Papyrus—one of the oldest surviving documents of ancient Egyptian medicine. The text describes a “cold, hard, immovable swelling of the breast,

NEJM: ~1–3% of patients in MS, IBD & AD trials were likely misdiagnosed and actually had a rare disease. Small numbers, but such misclassification could subtly confound observed treatment effects. Similar approaches could be used to identify potential misdiagnoses and refine

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer out on NEJM nejm.org/doi/full/10.10… IMvigor011 Presented at #ESMO25 showed that In patients with muscle-invasive #BladderCancer after cystectomy, ctDNA-🧬guided adjuvant therapy with atezolizumab significantly

Provocative study of ChemoIO for Omission of RT for stage III NSCLC(!) Evolution phase II study from Japan. In pts with PD-L1 TPS >50%, pembro+chemo induction and pembro maintenance had 2 yr PFS 67%, which arguably is comparable to PACIFIC. Is any local tx needed? #radonc

Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial annalsofoncology.org/article/S0923-… Randomized phase II trial evaluating 3🆚6 cycles of platinum-based chemotherapy

New #MetaAnalysis on metastatic hormone-sensitive #ProstateCancer (mHSPC): 👍Among 12,668 pts, triplet therapy (ARPI + Docetaxel + ADT) improves OS in synchronous high-volume disease. 👍For all other subgroups, ARPI + ADT is best. 👎No role for Docetaxel + ADT alone.